Programmed cell death 4 (Pdcd4) expression in colorectal adenocarcinoma: Association with clinical stage

Lim,Sung-Chul; Hong,Ran

doi:10.3892/ol.2011.365

Programmed cell death 4 (Pdcd4) expression in colorectal adenocarcinoma: Association with clinical stage

Authors:
- Sung-Chul Lim
- Ran Hong
View Affiliations

Affiliations: Department of Pathology, Chosun University Hospital, Gwangju 501-140, Republic of Korea
Published online on: July 22, 2011 https://doi.org/10.3892/ol.2011.365
Pages: 1053-1057

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to examine the role of Programmed cell death 4 (Pdcd4) in colorectal adenocarcinoma (CRA). Pdcd4 expression was observed in both the nucleus and cytoplasm in colorectal adenocarcinoma, whereas Pdcd4 was expressed in the nucleus in normal colonic epithelial cells. Loss or weak expression of Pdcd4 was identified in 44 cases (40.7%) of cancer cells. Pdcd4 expression was associated with an increase in the nodal and clinical stage (p=0.022 and p=0.016, respectively). Nuclear staining was identified in 66 cases (61.15%), with no correlation with clinicopathological factors. Conversely, cytoplasmic staining for Pdcd4 was observed in 45 cases (41.7%), and increased according to nodal and clinical stage (p=0.011 and p=0.009, respectively), indicating that aberrant Pdcd4 expression leads to tumor progression. However, Pdcd4 expression was not correlated to disease-free survival time. This study demonstrated that during the tumorigenesis of CRA, loss of nuclear Pdcd4 expression occurs, and during tumor progression, aberrant cytoplasmic expression is present, suggesting a higher clinical stage. Although loss of Pdcd4 was not significantly correlated with survival time, as the prognosis of colorectal cancer varies depending on clinical stage including invasion depth, nodal status and metastatic status, cytoplasmic Pdcd4 expression may be a favorable prognostic marker in CRA.

View Figures

View References

1	Jansen AP, Camalier CE and Colburn NH: Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 65:6034–6041. 2005. View Article : Google Scholar : PubMed/NCBI
2	Hilliard A, Hilliard B, Zheng SJ, et al: Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol. 177:8095–8102. 2006. View Article : Google Scholar : PubMed/NCBI
3	Yang HS, Matthews CP, Clair T, et al: Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol. 26:1297–1306. 2006. View Article : Google Scholar : PubMed/NCBI
4	Soejima H, Miyoshi O, Yoshinaga H, et al: Assignment of the programmed cell death 4 gene (Pdcd4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet. 87:113–114. 1999. View Article : Google Scholar : PubMed/NCBI
5	Cmarik JL, Min H, Hegamyer G, et al: Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA. 96:14037–14042. 1999. View Article : Google Scholar : PubMed/NCBI
6	Bitomsky N, Bohm M and Klempnauer KH: Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene. 23:7484–7493. 2004. View Article : Google Scholar : PubMed/NCBI
7	Goke R, Barth P, Schmidt A, Samans B and Lankat-Buttgereit B: Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol. 287:1541–1546. 2004. View Article : Google Scholar : PubMed/NCBI
8	Leupold JH, Yang HS, Colburn NH, Asangani I, Post S and Allgayer H: Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene. 26:4550–4562. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yang HS, Jansen AP, Nair R, et al: A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation. Oncogene. 20:669–676. 2001.PubMed/NCBI
10	Yang HS, Knies JL, Stark C and Colburn NH: Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene. 22:3712–3720. 2003. View Article : Google Scholar : PubMed/NCBI
11	Li T, Li D, Sha J, Sun P and Huang Y: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 383:280–285. 2001. View Article : Google Scholar : PubMed/NCBI
12	Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H and Afonja O: Alterations in the expression of Pdcd4 in ductal carcinoma of the breast. Oncol Rep. 18:1387–1393. 2007.PubMed/NCBI
13	Wei NA, Liu SS, Leung TH, et al: Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol Cancer. 8:702009. View Article : Google Scholar : PubMed/NCBI
14	Bohm M, Sawicka K, Siebrasse JP, Brehmer-Fastnacht A, Peters R and Klempnauer KH: The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene. 22:1905–1910. 2003. View Article : Google Scholar : PubMed/NCBI
15	Lankat-Buttgereit B, Gregel C, Knolle A, Hasilik A, Arnold R and Goke R: Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II. Mol Cell Endocrinol. 214:149–153. 2004. View Article : Google Scholar : PubMed/NCBI
16	Park JK, Hong R, Kim KJ, Lee TB and Lim SC: Significance of p-STAT3 expression in human colorectal adenocarcinoma. Oncol Rep. 20:597–604. 2008.PubMed/NCBI
17	Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual. 6th edition. Springer-Verlag; New York: pp. 157–164. 2002
18	Mudduluru G, Medved F, Grobholz R, et al: Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 110:1697–1707. 2007. View Article : Google Scholar
19	Yang HS, Jansen AP, Komar AA, et al: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 23:26–37. 2003. View Article : Google Scholar : PubMed/NCBI
20	Chen Y, Knosel T, Kristiansen G, et al: Loss of Pdcd4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol. 200:640–646. 2003. View Article : Google Scholar : PubMed/NCBI
21	Yoshinaga H, Matsuhashi S, Fujiyama C and Masaki Z: Novel human Pdcd4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 49:1067–1077. 1999. View Article : Google Scholar : PubMed/NCBI
22	Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM and Pekarsky Y: Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res. 65:11282–11286. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zhang H, Ozaki I, Mizuta T, et al: Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene. 25:6101–6112. 2005. View Article : Google Scholar : PubMed/NCBI